Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD and MAD study of VENT-02 in healthy volunteers
NL-OMON59801Phase 1Completed
- Sponsor
- Ventus Therapeutics
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of VENT-02 in Neuroinflammatory Disorders and Neurodegenerative disorders (NDDs), sponsored by Ventus Therapeutics. Started Jul 2023; status: completed.
02
Drugs
VENT-02
03
Conditions
Neuroinflammatory DisordersNeurodegenerative disorders (NDDs)
Beyond the preview
Go deeper on NL-OMON59801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59801.